ClinConnect ClinConnect Logo
Search / Trial NCT06781827

Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease

Launched by WECARE PROBIOTICS CO., LTD. · Jan 13, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the use of a probiotic called Lactobacillus reuteri to help prevent and treat Inflammatory Bowel Disease (IBD). The trial will last for 8 weeks, during which participants will take the probiotic. Researchers will closely monitor changes in the intestine by using special cameras and tests at different times—1 month, 3 months, 6 months, and 12 months after the treatment starts. They will also collect samples from the intestine and blood to look for signs of inflammation and to understand how the gut bacteria are changing.

To participate, you need to be at least 18 years old and diagnosed with IBD for between 3 months and 3 years. However, if you have other serious health issues, certain autoimmune diseases, or have used specific treatments like antibiotics in the last three months, you might not be eligible. If you decide to join, you can expect regular check-ups and tests to track your health during and after the treatment period. This trial aims to see if this probiotic can help improve the health of people with IBD, so your contribution could be valuable for future treatments.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Be over 18 years old
  • 2. Agree to sign informed consent; Have been diagnosed with IBD for at least 3 months but not more than 3 years -
  • Exclusion Criteria:
  • 1. Does not meet the diagnostic criteria of CD
  • 2. Patients with other autoimmune diseases, infectious diseases and malignant tumors Patients with CD during pregnancy and lactation; Patients with serious diseases of the liver, kidney, heart and lung, etc
  • 3. Patients with allergic diseases such as asthma and allergic rhinitis; alcoholic Patients with mental illness
  • 4. Patients with suspected cancer in their intestines
  • 5. Antibiotics, probiotics and prebiotics have been used in the past three months Had intestinal surgery (except appendicitis surgery)
  • 6. There is currently an infection
  • 7. He has had cancer in the last 5 years -

About Wecare Probiotics Co., Ltd.

wecare probiotics co., ltd. is a leading biotechnology firm dedicated to advancing gut health through innovative probiotic solutions. With a robust portfolio of research and development initiatives, the company focuses on formulating high-quality probiotic products that are backed by scientific evidence. Committed to enhancing the well-being of individuals, wecare probiotics collaborates with healthcare professionals and academic institutions to conduct clinical trials that evaluate the efficacy and safety of its formulations. The company's mission is to empower consumers with effective, research-driven probiotic options, fostering a healthier future for all.

Locations

Suqian, Jiangsu, China

Suqian, Jiangsu, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported